Clover Health’s first quarter was marked by strong membership expansion and a shift to positive profitability, which management attributed to robust enrollment during the annual election period and improved retention of existing members. CEO Andrew Toy emphasized that the company’s technology-driven care model, especially in its core New Jersey market, has been instrumental in fostering deeper clinical integration and operational efficiency. Management highlighted that these factors, along with enhanced benefit design and increased use of Clover Assistant, were central to the company’s improved operating margin and gross profit performance.
Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).
Clover Health (CLOV) Q1 CY2026 Highlights:
- Revenue: $749.2 million vs analyst estimates of $714.9 million (62% year-on-year growth, 4.8% beat)
- Adjusted EPS: $0.07 vs analyst estimates of $0.07 (in line)
- Adjusted EBITDA: $40.26 million vs analyst estimates of $32.87 million (5.4% margin, 22.5% beat)
- EBITDA guidance for the full year is $60 million at the midpoint, above analyst estimates of $56.02 million
- Operating Margin: 3.6%, up from -0.3% in the same quarter last year
- Customers: 155,773, up from 113,803 in the previous quarter
- Market Capitalization: $1.73 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Clover Health’s Q1 Earnings Call
- Richard Close (Canaccord Genuity) asked Interim CFO Clay Thornton what differentiated Clover’s business model. Thornton replied that taking full risk on its population and leveraging the broad PPO network via Clover Assistant were unique in the Medicare Advantage space.
- Richard Close (Canaccord Genuity) also asked about SG&A variability in the quarter. Thornton explained that nonrecurring expenses, including a claims adjustment reserve related to membership growth, impacted SG&A but are not expected to repeat.
- Jonathan Yong (UBS) questioned the development of new versus existing member cohorts, specifically regarding risk scores and health trends. Thornton responded that early indicators for both new and existing members were tracking in line or better than expected, particularly in inpatient and dental categories.
- Jonathan Yong (UBS) sought clarification on prior period development in claims and SG&A guidance. Thornton stated there was some modest unfavorable prior period development in the quarter and reaffirmed the company’s commitment to improving SG&A efficiency.
- No additional analyst questions on the call.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the pace at which new member cohorts mature and their impact on profitability, (2) the expansion and effectiveness of Clover Assistant and home-based care services in driving clinical outcomes and retention, and (3) the ability to sustain SG&A efficiency gains as the company scales. The trajectory of outpatient utilization and regulatory developments will remain important variables.
Clover Health currently trades at $3.26, up from $2.68 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
